Divis Laboratories Ltd
Divis Laboratories Q2 Results 2026 (FY27): Revenue ₹3770 Cr, PAT ₹1,127 Cr
Q2 FY27 results statement: what the company reported on revenue, margins and capex.
- Revenue
- ₹3,676Cr
- Net profit
- ₹1,127Cr
- Margin
- 42.6%
Guidance rank: #53 of 87 in Pharmaceuticals & Biotechnology
See the sector's top 10 — free with your mobile number.
Based on Divis Laboratories Ltd's Q2 FY27 results statement. The company has not published an earnings-call transcript for this quarter, so figures here are what the results statement reports, not management guidance.
The short version
For Q2 FY27 ended September 30, 2026, Divi's Laboratories reported:. EBITDA for the quarter ended Sep 30, 2026: ₹1,785 crores (calculated as Profit before exceptional items and tax ₹1,505 crores + Depreciation & amortisation ₹142 crores + Finance costs ₹13 crores + A.
From Divis Laboratories Ltd's Q2 FY27 earnings-call transcript · updated 7 Nov 2026.
How did Divis Laboratories' revenue grow in the September 2026 quarter?
- For Q2 FY27 ended September 30, 2026, Divi's Laboratories reported:
- Consolidated total income: ₹3770 crores
- Previous year Q2 total income: ₹2860 crores
2 more points from Divis Laboratories Ltd's call on revenue
Create a free account to keep reading this call
What happened to Divis Laboratories' margins in Q2 FY27?
See what Divis Laboratories Ltd said on profitability & margins — free account, 30 seconds.
What capex is Divis Laboratories planning?
See what Divis Laboratories Ltd said on capital expenditure plans — free account, 30 seconds.
Top-ranked in Pharmaceuticals & Biotechnology
Ranked on what management guided this quarter
Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
Is Divis Laboratories raising money or cutting debt?
See what Divis Laboratories Ltd said on fundraising & capital structure — free account, 30 seconds.
How big is Divis Laboratories' order book?
See what Divis Laboratories Ltd said on order book & pipeline — free account, 30 seconds.
Divis Laboratories Ltd — Quarterly revenue & net profit
Divis Laboratories Ltd Q2 FY27 results — key figures
| ₹ Cr | Q2 FY27 |
|---|---|
| Revenue | 3,676 |
| Operating profit (EBITDA) | 1,566 |
| Operating margin | 42.6% |
| Profit before tax | 1,505 |
| Net profit (PAT) | 1,127 |
| EPS (₹) | 42.49 |
Source: Divis Laboratories Ltd's results filing to NSE (consolidated), ₹ crore.
Reported quarterly figures (₹ Cr). Latest (Q2 FY27): revenue ₹3.7K Cr, net profit ₹1.1K Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.
Full financials →Continue your research
What Divis Laboratories's management said in earlier quarters
Others in Pharmaceuticals & Biotechnology this season
- Infinium Pharma (Q2 FY27)
3,940.98 Lacs (about 54.3% increase) . Key results statement takeaways from Infinium Pharmachem Ltd's Q2 FY27 results statement — and how it ranks against secto
- Walpar Nutrition (Q2 FY27)
3,631.14 Lakhs for the half year ended September 30, 2025, reflecting a year-on-year increase of approximately 13.79%. Key results statement takeaways from Walp
- Kilitch Drugs (Q2 FY27)
14.3%) . Key results statement takeaways from Kilitch Drugs (India) Ltd's Q2 FY27 results statement — and how it ranks against sector peers.
- NGL Fine Chem (Q2 FY27)
Consolidated: ₹15,870.73 lakhs . Key results statement takeaways from NGL Fine Chem Ltd's Q2 FY27 results statement — and how it ranks against sector peers.
Potential multibaggers · Q2 FY27
Potential multibaggers in Pharmaceuticals & Biotechnology
on management's own guidance
- Strong growth2
- Strong growth1
- Strong growth3
Portfolio builder
Build your portfolio
from the top-ranked stocks
- 1. Pick 3–15 stocks
- 2. Choose large, mid or small cap and your sectors
- 3. Get a portfolio built from the rankings
Ranks describe management commentary on revenue and margin from the latest earnings call. Not investment advice.
Arthneeti Pro · Annual
Divis Laboratories Ltd and 15K+ more earnings calls,
for less than your morning chai
a day
Every earnings call, ranking and concall Q&A across all four results seasons.
Secure Razorpay payment · instant access
Frequently Asked Questions
What were Divis Laboratories Ltd Q2 FY27 results?
For Q2 FY27 ended September 30, 2026, Divi's Laboratories reported:. EBITDA for the quarter ended Sep 30, 2026: ₹1,785 crores (calculated as Profit before exceptional items and tax ₹1,505 crores + Depreciation & amortisation ₹142 crores + Finance costs ₹13 crores + A.
What is Divis Laboratories Ltd share price analysis?
Divis Laboratories Ltd currently shows a neutral. The stock trades at a P/E of 92.0 with a market cap of ₹273,977 Cr. Investors should review the full earnings analysis for detailed insights.
Keep Divis Laboratories Ltd on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and the company's results statement. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.